Wednesday, September 28, 2016

Zarontin


Zarontin is a brand name of ethosuximide, approved by the FDA in the following formulation(s):


ZARONTIN (ethosuximide - capsule; oral)



  • Manufacturer: PARKE DAVIS

    Approved Prior to Jan 1, 1982

    Strength(s): 250MG [RLD][AB]

Has a generic version of Zarontin been approved?


Yes. The following products are equivalent to Zarontin:


ethosuximide capsule; oral



  • Manufacturer: BANNER PHARMACAPS

    Approval date: October 28, 2002

    Strength(s): 250MG [AB]


  • Manufacturer: VERSAPHARM

    Approval date: May 28, 2008

    Strength(s): 250MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zarontin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Zarontin.

See also...

  • Zarontin Consumer Information (Wolters Kluwer)
  • Zarontin Solution Consumer Information (Wolters Kluwer)
  • Zarontin Consumer Information (Cerner Multum)
  • Zarontin Advanced Consumer Information (Micromedex)
  • Zarontin AHFS DI Monographs (ASHP)
  • Ethosuximide Consumer Information (Wolters Kluwer)
  • Ethosuximide Solution Consumer Information (Wolters Kluwer)
  • Ethosuximide Consumer Information (Cerner Multum)
  • Ethosuximide Advanced Consumer Information (Micromedex)
  • Ethosuximide AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Ultram ER


See also: Generic Ultram


Ultram ER is a brand name of tramadol, approved by the FDA in the following formulation(s):


ULTRAM ER (tramadol hydrochloride - tablet, extended release; oral)



  • Manufacturer: VALEANT INTL

    Approval date: September 8, 2005

    Strength(s): 100MG [RLD][AB1], 200MG [AB1], 300MG [AB1]

Has a generic version of Ultram ER been approved?


Yes. The following products are equivalent to Ultram ER:


tramadol hydrochloride tablet, extended release; oral



  • Manufacturer: LUPIN LTD

    Approval date: August 29, 2011

    Strength(s): 100MG [AB1], 200MG [AB1], 300MG [AB1]


  • Manufacturer: PAR PHARM

    Approval date: November 13, 2009

    Strength(s): 100MG [AB1], 200MG [AB1]


  • Manufacturer: PAR PHARM

    Approval date: September 20, 2011

    Strength(s): 300MG [AB1]


  • Manufacturer: SUN PHARMA GLOBAL

    Approval date: December 7, 2011

    Strength(s): 100MG [AB1], 200MG [AB1], 300MG [AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultram ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ultram ER.

See also...

  • Ultram ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Ultram ER Consumer Information (Cerner Multum)
  • Ultram ER Advanced Consumer Information (Micromedex)
  • Tramadol Consumer Information (Drugs.com)
  • Tramadol Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Consumer Information (Cerner Multum)
  • FusePaq Synapryn Advanced Consumer Information (Micromedex)
  • Tramadol Advanced Consumer Information (Micromedex)
  • Tramadol Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Tri-Luma


Tri-Luma is a brand name of fluocinolone/hydroquinone/tretinoin topical, approved by the FDA in the following formulation(s):


TRI-LUMA (fluocinolone acetonide; hydroquinone; tretinoin - cream; topical)



  • Manufacturer: GALDERMA LABS LP

    Approval date: January 18, 2002

    Strength(s): 0.01%;4%;0.05% [RLD]

Has a generic version of Tri-Luma been approved?


No. There is currently no therapeutically equivalent version of Tri-Luma available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tri-Luma. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Topical skin care composition
    Patent 7,915,243
    Issued: March 29, 2011
    Inventor(s): Puglia; Nancy & Ramirez; Rosario & Roth; Jerry
    Assignee(s): Galderma S.A.
    A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Patent expiration dates:

    • March 22, 2026
      ✓ 
      Drug product




  • Topical skin care composition
    Patent 7,939,516
    Issued: May 10, 2011
    Inventor(s): Puglia; Nancy & Roth; Jerry & Ramirez; Rosario
    Assignee(s): Galderma S.A.
    A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Patent expiration dates:

    • May 4, 2025
      ✓ 
      Drug product



See also...

  • Tri-Luma Consumer Information (Wolters Kluwer)
  • Tri-Luma Consumer Information (Cerner Multum)
  • Fluocinolone/Hydroquinone/Tretinoin Consumer Information (Wolters Kluwer)
  • Fluocinolone, hydroquinone, and tretinoin topical Consumer Information (Cerner Multum)
Posted by at No comments:
Labels:

Diogam




Diogam may be available in the countries listed below.


Ingredient matches for Diogam



Diosmin

Diosmin is reported as an ingredient of Diogam in the following countries:


  • Tunisia

International Drug Name Search

Posted by at No comments:
Labels:

femhrt


femhrt is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):


FEMHRT (ethinyl estradiol; norethindrone acetate - tablet; oral)



  • Manufacturer: WARNER CHILCOTT

    Approval date: October 15, 1999

    Strength(s): 0.005MG;1MG [RLD][AB]


  • Manufacturer: WARNER CHILCOTT

    Approval date: January 14, 2005

    Strength(s): 0.0025MG;0.5MG

Has a generic version of femhrt been approved?


Yes. The following products are equivalent to femhrt:


NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL (ethinyl estradiol; norethindrone acetate tablet; oral)



  • Manufacturer: BARR

    Approval date: November 6, 2009

    Strength(s): 0.005MG;1MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of femhrt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with femhrt.

See also...

  • Femhrt Consumer Information (Drugs.com)
  • Femhrt Consumer Information (Wolters Kluwer)
  • Femhrt 1 mg/5 mcg HRT Consumer Information (Cerner Multum)
  • Femhrt 1/5 HRT Consumer Information (Cerner Multum)
  • Femhrt HRT Consumer Information (Cerner Multum)
  • Ortho-Novum Consumer Information (Drugs.com)
  • Norethindrone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol (HRT) Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol Chewable Tablets Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol Tablets Consumer Information (Wolters Kluwer)
  • Ethinyl estradiol and norethindrone Consumer Information (Cerner Multum)
  • Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
  • Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Pataday


Pataday is a brand name of olopatadine ophthalmic, approved by the FDA in the following formulation(s):


PATADAY (olopatadine hydrochloride - solution/drops; ophthalmic)



  • Manufacturer: ALCON PHARMS LTD

    Approval date: December 22, 2004

    Strength(s): EQ 0.2% BASE [RLD]

Has a generic version of Pataday been approved?


No. There is currently no therapeutically equivalent version of Pataday available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pataday. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Topical ophthalmic formulations for treating allergic eye diseases
    Patent 5,641,805
    Issued: June 24, 1997
    Inventor(s): Hayakawa; Eiji & Nakakura; Masashi & Robertson; Stella M. & Yanni; John Michael
    Assignee(s): Alcon Laboratories, Inc.
    Kyowa Hakko Kogyo Co. Ltd.
    Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
    Patent expiration dates:

    • June 6, 2015
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS


    • December 6, 2015
      ✓ 
      Pediatric exclusivity




  • Olopatadine formulations for topical administration
    Patent 6,995,186
    Issued: February 7, 2006
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:

    • November 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
      ✓ 
      Drug product


    • May 12, 2024
      ✓ 
      Pediatric exclusivity




  • Olopatadine formulations for topical administration
    Patent 7,402,609
    Issued: July 22, 2008
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:

    • June 19, 2022
      ✓ 
      Drug product


    • December 19, 2022
      ✓ 
      Pediatric exclusivity



See also...

  • Pataday Drops Consumer Information (Wolters Kluwer)
  • Pataday Consumer Information (Cerner Multum)
  • Pataday Advanced Consumer Information (Micromedex)
  • Olopatadine Drops Consumer Information (Wolters Kluwer)
  • Olopatadine ophthalmic Consumer Information (Cerner Multum)
  • Olopatadine Ophthalmic Advanced Consumer Information (Micromedex)
  • Olopatadine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Jalyn


Jalyn is a brand name of dutasteride/tamsulosin, approved by the FDA in the following formulation(s):


JALYN (dutasteride; tamsulosin hydrochloride - capsule; oral)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: June 14, 2010

    Strength(s): 0.5MG;0.4MG [RLD]

Has a generic version of Jalyn been approved?


No. There is currently no therapeutically equivalent version of Jalyn available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jalyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Androstenone derivative
    Patent 5,565,467
    Issued: October 15, 1996
    Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:

    • November 20, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Androstenone derivative
    Patent 5,846,976
    Issued: December 8, 1998
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:

    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY




  • Androstenones
    Patent 5,998,427
    Issued: December 7, 1999
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
    Patent expiration dates:

    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
      ✓ 
      Drug substance
      ✓ 
      Drug product



See also...

  • Jalyn Consumer Information (Drugs.com)
  • Jalyn Consumer Information (Wolters Kluwer)
  • Jalyn Consumer Information (Cerner Multum)
  • Jalyn Advanced Consumer Information (Micromedex)
  • Dutasteride/Tamsulosin Consumer Information (Wolters Kluwer)
  • Dutasteride and tamsulosin Consumer Information (Cerner Multum)
  • Dutasteride and tamsulosin Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)